. 2011 Dec 9;25(4):537–547. doi: 10.1038/modpathol.2011.188

Table 1. Sensitivity and specificity of immunohistochemistry with CI; sensitivity is defined as the proportion of follicular carcinoma patients who expressed the marker in tumor, and specificity as the proportion of patients with follicular adenoma, who did not express the marker³¹.

	Sensitivity	95% CI	Specificity	95% CI
(a) In-house cases
DDIT3	1.00	—	0	—
STT3Ap	1.00	—	0	—
STT3Am	1.00	—	0	—
ARG2	0.40	0.29–0.64	0.80	0.55–0.93
FAM129Ap	0.87	0.62–0.96	0.40	0.20–0.64
FAM129Am	0.33	0.15–0.58	0.87	0.62–0.96

(b) Tissue microarray cases
DDIT3	1.00	—	0.24	0.11–0.45
STT3Ap	1.00	—	0.14	0.05–0.35
STT3Am	1.00	—	0.19	0.08–0.40
ARG2	0.12	0.02–0.47	0.90	0.71–0.97
FAM129Ap	1.00	—	0.19	0.08–0.40

Abbreviation: CI, confidence intervals.

Table 1. Sensitivity and specificity of immunohistochemistry with CI; sensitivity is defined as the proportion of follicular carcinoma patients who expressed the marker in tumor, and specificity as the proportion of patients with follicular adenoma, who did not express the marker31.